Deletion of Prostaglandin E2 EP2 Receptor Protects against Ultraviolet-Induced Carcinogenesis, but Increases Tumor Aggressiveness  by Brouxhon, Sabine et al.
Deletion of Prostaglandin E2 EP2 Receptor Protects
against Ultraviolet-Induced Carcinogenesis, but
Increases Tumor Aggressiveness
Sabine Brouxhon1, Raymond L. Konger2, JoAnne VanBuskirk3, Tzong-jen Sheu4, Julie Ryan3, Brandon Erdle3,
Anthony Almudevar5, Richard M. Breyer6, Glynis Scott3 and Alice P. Pentland3
Ultraviolet (UV) light is a complete carcinogen inducing and promoting squamous-cell carcinoma (SCC) of the
skin. Recent work has shown that SCC initiation and promotion are enhanced by prostaglandin E2 (PGE2). PGE2
interacts with specific EP receptors to regulate cellular functions. Previous work from our group has shown that
the prostaglandin E2 EP2 receptor is a powerful regulator of keratinocyte growth. SKH-1 hairless mice lacking the
EP2 receptor were therefore studied to understand how this growth signaling pathway contributes to
photocarcinogenesis. Our data indicate that UV-irradiated mice lacking EP2 receptors exhibit decreased
proliferation and a poor capacity for epidermal hypertrophy in response to UV injury. In a chronic irradiation
model, these animals were protected from tumor formation, developing 50% fewer tumors than wild-type
controls. Despite this capacity to protect against tumorigenesis, animals lacking EP2 receptors grew tumors that
were larger in size, with a more aggressive phenotype. Further study suggested that this susceptibility may be
associated with synthesis of active metalloproteinase enzymes in greater quantities than keratinocytes
expressing the EP2 receptor, thereby enhancing the invasive potential of EP2
/ cells.
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INTRODUCTION
Skin cancer is the most common form of cancer, and its
incidence is on the rise (Geller and Annas, 2003). The primary
cause of skin cancer is ultraviolet (UV) light exposure. UV
light (Martinez et al., 2003) is a complete carcinogen,
inducing and promoting squamous-cell carcinoma (SCC) of
the skin (Saladi and Persaud, 2005). Recent work has shown
that SCC promotion is enhanced by prostaglandin E2 (PGE2)
(Rao et al., 1995; Marks and Furstenberger, 2000; Umar et al.,
2001; Bresalier, 2002; Kawamori and Wakabayashi, 2002).
As non-steroidal anti-inflammatory drugs act by inhibiting the
formation of PGE2, it is possible that useful skin cancer
chemopreventive effects can be produced through the use of
non-steroidal anti-inflammatory drugs and new more selective
therapeutic agents influencing the activity of prostaglandin
receptors (Fischer et al., 1999; Pentland et al., 1999; DuBois,
2001; Sonoshita et al., 2002). Non-selective drugs affecting
this class of compounds have been used effectively with
relative safety for decades, but recent information has shown
an excess risk of heart attack results from use of some selective
inhibitors (Lenzer, 2004; Egan et al., 2005; Furberg et al.,
2005). Clearly, deeper understanding of PGE2 contributions to
cancer can be translated into therapeutic strategies with
immediate, broad, and beneficial impact if a better knowledge
of specific risk and benefit can be obtained.
PGE2 initiates cellular responses by stimulating specific EP
receptors. These receptors, designated EP1–4, are divided into
four subtypes that differ in ligand-binding specificity, tissue
distribution, and coupling to intracellular signal transduction
pathways reviewed by Hata and Breyer (2004). Human
keratinocytes express both growth-stimulatory (EP2) and
growth-inhibitory (EP1, EP3) receptors for PGE2 (Konger
et al., 1998, 2002, 2005). Our data show that EP3 receptor
stimulation decreases proliferation at low PGE2 concentra-
tions, whereas 10- to 100-fold higher concentrations of PGE2
stimulate proliferation by activation of the EP2 receptor
(Konger et al., 1998). Receptor activity appears to depend
upon the level of PGE2 in the epidermis regardless of the
isoform of cyclooxygenase (COX) expressed. This suggests
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that EP receptors, rather than COX, may be a better
therapeutic target for chemoprevention of skin cancer.
As the EP2 receptor has been shown to be the major growth
stimulatory prostaglandin receptor in the epidermis, we
studied the effect of EP2 receptor disruption on the responses
to acute and chronic UV injury in SKH hairless mice. Our
work suggests that absence of EP2 receptor signaling may be
helpful in early stages of tumorigenesis, but can augment the
aggressive characteristics of SCC once tumors have become
invasive and achieved larger sizes.
RESULTS
Characterization of UV effects on WT versus EP2
/ mice
A series of experiments were performed to characterize EP2-
mediated keratinocyte responses in a UV injury model. Initial
studies examined the acute effects of UV injury on epidermal
hypertrophy, proliferation, and PGE2 synthesis. WT, EP2
þ /,
and EP2
/ animals were exposed to UV light, then killed at
intervals to assess their response. Animals were exposed to
either 180, 270, or 360 mJ/cm2 UVR, then killed 24, 72, and
96 hours or 1 week later. A dose of 180 mJ/cm2 is equivalent
to approximately 1 hour of noonday sun exposure in
Rochester, NY. Exposure to 180 mJ/cm2 UVR increased the
PGE2 detected two-fold 24 hours post UVR in samples of
snap-frozen epidermis (control¼ 10075 pg/mg protein,
UV¼20078 pg/mg protein), returning to near baseline by
72 hours (120715 pg/mg tissue). This 180 mJ/cm2 dose
represents moderate exposure, whereas the 360 mJ/cm2 dose
produced a brisk, non-blistering sunburn-like response.
Animals appeared comfortable after exposure to each dose
of light given. At the highest dose of light, some edema was
evident on the animals’ mid-back area before the killing at
the 72 hours time point.
Initial analysis of BrdU incorporation data indicated that
the largest alterations were present 72 hours after UVR
exposure. This time point was therefore selected to assess
genotype effects on UVR-stimulated keratinocyte prolifera-
tion. A brisk induction of BrdU incorporation was produced
by irradiation in WT animals at all UVR exposure levels
tested, 180, 270, and 360 mJ/cm2 UVR. Induction of
keratinocyte proliferation after 270 and 360 mJ/cm2 UVR in
EP2
/ mice was similar to that observed in WT animals (data
not shown). However, after a modest 180 mJ/cm2 UVR
exposure, proliferation in heterozygous or knockout animals
was significantly decreased compared to controls (Figure 1).
No difference in the incorporation of label in EP2
/ mice was
present compared to unirradiated controls. UVR produced
significant induction of proliferation in wild–type (WT)
animals, and the response of heterozygote animals was
halfway between this amount and the proliferation present
in unirradiated WT mice and UVR-exposed EP2
/ mice.
Thus, EP2
/ mice appeared less able to increase their
proliferation in response to modest UVR exposures, but were
able to increase their proliferation to the same extent as
controls when a larger UVR dose provided a stronger
proliferative stimulus.
As the proliferative response to irradiation was increased
by UVR exposure, epidermal thickness was measured in each
animal 72 hours after exposure, when the proliferative
response was maximal (Table 1). Care was taken to measure
the thickness in true vertical sections from the portion of the
back in which the greatest degree of epidermal hypertrophy
was observed. These data showed that genotype had a
modest influence on hypertrophy in animals exposed to the
moderate 180 mJ/cm2 dose of light and suggest that the
proliferative response in EP2
/ animals may end earlier in
than in WT animals. However, in animals exposed to larger
doses of light, an impairment of the hypertrophic response
was observed in EP2
þ / and EP2
/ animals when compared
with controls. After exposure to 360 mJ/cm2 UV, EP2
/
animals were only able to increase epidermal thickness
two-fold, whereas WT animals increased their epidermal
thickness nearly six-fold.
Loss of EP2 decreases UV-induced tumor numbers but increases
tumor aggressiveness
Tumor formation was produced using a classical photocarci-
nogenesis model in which animals were exposed to escalat-
ing doses of light for 15 weeks, then monitored for an
additional 15 weeks to observe tumor growth (Pentland et al.,
WT
EP2 +/–
EP2 –/–
7
6
5
4
3
2
1
0
Control 72 hours 180 mJ/cm2
Br
dU
-p
os
itiv
e
 c
e
lls
/1
0,
00
0 
M
Figure 1. Modest UVR exposure does not stimulate proliferation in EP2
/
mice. Proliferation present in the epithelium of WT, EP2
þ /, and EP2
/ animals
was determined 72 hours post UV-irradiation. Animals were exposed to either
no light (control), or to 180 mJ/cm2 UVR. UV-induced proliferation in WT
animals is significantly different from that in EP2
/, Po0.05, Students t-test.
Data are expressed as the mean7SEM. N¼ 4.
Table 1. Decreased capacity for EP2 receptor-
deficient animals to produce epidermal hypertrophy
after irradiation
WT EP2
+/ EP2
/
Epidermal thickness (mM) 72 h after UV exposure
Control 23.671.3 22.271.5 21.970.7
180 mJ/cm2 78.974.7 78.977.1 68.677.8*
270 mJ/cm2 89.175.5 63.477.3* 53.875.2*
360 mJ/cm2 113.874.7 45.276.0* 34.775.6*
UV, ultraviolet; WT, wild type.
Values shown are 7SEM, N=4.
*Value is significantly different than WT control, Po0.05, Student’s t-test.
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1999, 2004). Total tumor numbers, tumors per mouse, tumor
incidence, time of tumor onset, and tumor size were tracked
in these studies. A significant protective effect of EP2 receptor
deletion was observed in EP2
/ mice (Figure 2). Over
the period of observation, WT animals developed twice as
many tumors as EP2
/ animals. Interestingly, protection
against tumor formation was not observed in heterozygous
animals (Figure 2). Protection of EP2
/ animals from tumor
formation did not affect the time of tumor onset or tumor
multiplicity.
Despite the protection from tumor formation observed in
EP2
/ mice, a difference in the clinical appearance of the
tumors was observed. On gross observation, the larger lesions
in EP2
/ animals were present in greater numbers, more
erythematous, and had less keratinization. Detailed analysis
of all tumor sizes confirmed this impression. In Table 2, the
number of tumors in each size range are shown: 1–5, 6–9, and
410 mm diameter. Significantly more very large tumors were
noted in the EP2
/ animals, whereas more small tumors are
present in WT animals. Gross observation of the tumors
suggested that this difference might be due to the degree of
tumor differentiation in WT versus EP2
/ animals. Inspection
of tumor histology by a dermatopathologist was therefore
done to determine whether animal genotype affected the
degree of tumor differentiation. Sections of tumors 45 mm
were taken from the accessible surface of all paraffin-
embedded tissue blocks (see Materials and Methods). The
slides were blinded before analysis, then characterized as
either well differentiated or moderately/poorly differentiated
(Table 3). A total of eight tumors were available from WT
animals, and seven from EP2
/ animals. Well-differentiated
tumors were those with clear evidence of keratinization and
were more superficially invasive. Moderate to poorly
differentiated tumors were deeply invasive, had less obvious
keratinization, and were frequently spindled, consistent with
a more aggressive phenotype (Petter and Haustein, 2000).
The WT animals were more likely to have well-differentiated
tumors than EP2
/ animals. The morphology of the tumors in
EP2
/ animals was often spindled and deeply invasive. The
presence of some keratinization, even in spindled tumors,
was consistent with SCC. Although the EP2
/ animals’ tumors
had a more aggressive morphology, there was no evidence
of metastasis to lung, liver, or regional lymph nodes in four
EP2
/ animals bearing large tumors.
Loss of EP2 alters MMP expression
Expression of extracellular matrix remodeling enzymes are
thought to have an important role determining the capacity of
cells to move through the extracellular space. Extracts of
snap-frozen control and acutely irradiated mouse epidermis
were therefore examined for matrix metalloproteinase (MMP)
activity. Specific fluorescent substrates of MMP-2 and MMP-9
were incubated with the epidermal extracts as described in
the Materials and Methods. In the presence of MMP, these
substrates emit light at 440 nm when stimulated at 340 nm.
The data from these experiments revealed that EP2
/ animals
had increased activity of both MMP-2 and MMP-9 after UV
exposure (Figure 3).
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Figure 2. EP2 deletion protects against UV-induced tumors. Mice were
photographed after completion of the 30-week UV-irradiation protocol.
(a) Total tumors per mouse were tracked weekly for 15 weeks after cessation
of UVR. Using a Mann–Whitney test, a statistically significant difference was
seen between the WT and the EP2
þ / and WT or EP2
þ / mice (Po0.01). No
statistically significant difference was evident between the WT and the EP2
þ /
genotype (N¼ 10), EP2þ / (N¼ 9) and EP2/ (N¼ 10). Data are expressed as
the mean þ /- SEM. (b) Progressive tumor incidence in WT, EP2þ /, and EP2þ /
mice. No significant differences were observed. (c) Representative tumors on
UVR exposed mice of each genotype.
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To confirm the changes observed using the catalysis assay,
zymography was also used to characterize the impact of EP2
receptor deletion on epidermal MMP activity after UV
exposure (Figure 4). MMP activity in WT and EP2
/ was
again compared 24 hours after UV irradiation. In WT
animals, exposure to 180 mJ/cm2 UVR resulted in little
increase in the expression of pro- and activated MMP-2 by
24 hours. In contrast, when MMP-2 was measured in extracts
of epidermis from animals lacking EP2 receptor, the quantity
of MMP-2 was low at baseline. After UV exposure, pro-MMP-
2 increased to about the same level as that seen in
WT animals after UV exposure. However, the amount of
active MMP-2 was substantially increased. In agreement
with the findings obtained using activity assays, changes in
MMP-9 expression were also observed in zymograms of
epidermal curettings. Extracts from WT animals contained
very little MMP-9 activity, and UV exposure did not alter its
expression. In contrast, although EP2
/ animals had similar
amounts of enzyme as WT animals before UV exposure,
there was a pronounced increase in MMP-9 after UV
exposure.
DISCUSSION
Many lines of evidence indicate that enhanced synthesis of
PGE2 increases tumor risk, and that interventions that
decrease prostaglandin synthesis are helpful. For example,
COX-2 knockout mice have been found to have fewer tumors
than WT controls in several different cancer models. In
antigen-presenting cell-deficient animals, the incidence of
colon cancer is reduced 50% in animals also lacking the
COX-2 gene (Williams et al., 1999). Similar results are
obtained in skin using a chemical carcinogenesis approach
(Tiano et al., 2002). Treatments with selective COX-2
inhibitors produce similar levels of protection in a variety of
cancer models, photocarcinogenesis, colon, cervix, and
breast (Marks and Furstenberger, 2000; Sales et al., 2001;
Rao et al., 2002; Singh-Ranger and Mokbel, 2002). Thus, it is
clear that decreasing PGE2 synthesis for cancer chemo-
prevention could have extensive beneficial impact.
Recent events have shown that this potential benefit is not
without risk. In some clinical trials, increases in heart attack
and stroke incidence resulted in manufacturers pulling
selective COX-2 inhibitors from the market (Fitzgerald,
2004; Lenzer, 2004; Furberg et al., 2005). These events
clearly indicate that better understanding of the functional
Table 2. Enhanced tumor size in EP2
/ mice exposed
to chronic UVR
Tumor size WT (n=10) +/(n=9) /(n=10)
1–5 102 87 55
6–9 mm 9 9 5
X10 mm 1 0 5*
UVR, ultraviolet radiation; WT, wild type.
Greater numbers of tumors 4 10 mm were observed in EP2
/ mice.
*Two sided P-value p0.02 using Fisher’s exact test.
Table 3. Histology of tumors present in wild-type
versus EP2
/ mice
WT EP2
/
Well differentiated 7 3
Moderate/poorly differentiated 1 4
WT, wild type.
The morphology of tumors 45 mm in size was examined. Tumors from
eight wild-type and seven EP2
/ mice were assessed to determine
differentiation.
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Figure 3. MMP-2 and MMP-9 activity is increased in epidermal extracts
of EP2
/ animals. UVR produces net increases in the activities of MMP-2
and MMP-9 in EP2
/ animals compared to WT animals 24 hours after UV
exposure. Activity returns to baseline 72 hours post UVR. Data are expressed
as the mean7SEM in a representative experiment. N¼2.
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Figure 4. UVR-induction of MMP-2 and MMP-9 is increased in EP2
/
animals compared to WT controls. Snap-frozen epidermal extracts from
control and UV-exposed WT and EP2
/ animals were studied at baseline
and 24 hours after UV exposure as described in Materials and Methods.
A representative zymogram is shown. N¼ 4.
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impact of modifying PGE2 production is important. One line
of investigation that can illuminate the mechanisms by which
PGE2 modulates cancer progression is work defining the
effects of EP receptor deletion on mouse cancer models. To
date, some work delineating the role of EP1, EP2, EP3, and EP4
receptors in colon cancer progression has been done (Mutoh
et al., 2002; Kawamori et al., 2005; Shoji et al., 2004, 2005).
Recent work by Sung et al. (2005) also indicate that deletion
of the EP2 receptor protects against skin tumor formation and
influences epidermal thickness in a chemical carcinogenesis
model. In that study, there was no effect of genotype on
tumor aggressiveness or size. We have previously shown that
significant differences in results occur when a photocarcino-
genesis model is studied versus a chemical carcinogenesis
model (Pentland et al., 2004). The work presented here
extends this information to include EP2 receptor effects in a
mouse photocarcinogenesis model.
The EP2 receptor is linked to cAMP signaling and
has a higher Kd than other PGE receptors. Its signaling is
therefore likely to be activated when COX-2 synthesis is
increased, and PGE2 production increases concurrently. In
the work presented here, there are clear benefits from
EP2 signaling after acute UV injury to augment recovery
from injury. Our work demonstrates EP2 signaling increases
the capacity to replace damaged cells and thicken the
epidermis, the organ primarily responsible for filtering
the penetration of harmful UV light into skin. However,
these acute benefits appear to be associated with some long-
term risk. Animals expressing normal EP2 receptors are twice
as likely to develop tumors in response to UV when
compared to EP2
/ animals. On first glance, blockade of
EP2 receptor signaling would appear to be helpful. The risks
in this strategy are also evident in the current studies. When
EP2
/ animals do develop tumors, they become larger,
despite the apparently poorer proliferative response of
EP2
/ epithelium to acute injury. In addition, the tumors
examined in the EP2
/ mice were more likely to exhibit an
aggressive, invasive, spindled phenotype.
To understand what consequence of receptor deletion
might account for this more aggressive tumor phenotype in
EP2
/ mice, regulation of enzymes responsible for matrix
remodeling were examined. Keratinocytes are capable of
synthesizing an assortment of metalloproteinases important in
wound repair (Saarialho-Kere et al., 1994; Steffensen et al.,
2001; Nova et al., 2003; Sawicki et al., 2005). A key
regulator of their ability to remodel extracellular matrix is
their capacity to synthesize matrix-degrading enzymes as
well as their inhibitors, TIMP-1, TIMP-2, and TIMP-3. Work
by Baratelli et al. (2004) has shown that PGE2/EP2 receptor-
dependent signaling decreases dendritic cell migration in
animals via enhancement of TIMP-1, presumably thus
hampering tumor antigen presentation. Recent studies have
also linked–SSC cancer tumor invasion and presence of type
VII collagen fragments in patients with Epidermolysis Bullosa
(Ortiz-Urda et al., 2005). These patients have a congenital
defect in type VII collagen synthesis. The keratinocytes of
those patients with residual truncated aminoterminal non-
collagenous domain of type VII protein have been shown to
produce–SSC in a ras-driven mouse tumorigenesis model. In
contrast, keratinocytes from those patients without such
truncated protein do not form tumors. The authors further
demonstrate that fibronectin-like sequences within the non-
collagenous domain promoted tumor cell invasion in a
laminin 5-dependent manner.
In the current study, we observe increased risk of
aggressive tumors in EP2
/ animals in association with
enhanced MMP-2 and MMP-9 activity and production. Each
of these enzymes is capable of cleaving an array collagen
types (Overall, 2002). Of interest, these enzymes are both
capable of cleaving type VII collagen, which Ortiz-Urda et al.
(2005) have shown can enhance SSC invasion, suggesting a
mechanism for increased tumor aggressiveness and size in
EP2
/ animals. Although this proposed mechanism remains
speculative, and other unexplored mechanisms are likely to
also be important, what has been clearly demonstrated in this
study is that targeted blockade of EP2 receptor signaling by
itself may initially slow tumor growth, but with unacceptable
consequences for useful chemoprevention in the clinical
setting.
MATERIALS AND METHODS
Animals
EP2
/ animals were generated by Dr. Richard Breyer, as described
(Kennedy et al., 1999). These mice were initially in a C57bl6/SV129
background and were backcrossed for seven generations into SKH-1
mice (Charles River Laboratories, Wilmington, MA) to create albino
hairless mice lacking EP2. Outbred SKH-1 mice are the standard
strain used for photocarcinogenesis work (Black et al., 1997). The
SKH-1 hairless mouse has a defect in hair catagen regulation
(Panteleyev et al., 1999). In all other respects, the skin of this mouse
is considered normal and is not immunocompromised. Genetic
typing of 97 markers in five representative animals demonstrated that
73% of the loci tested were identical among the animals, and
another 17% were heterozygous when tested against C57Bl6 genetic
markers. Genotyping by PCR to identify knockout mice was
performed using the primers indicated:
EP2 WT sense (5
0 to 30) GAG AGC GAC CGG ATA TTG TAG TGA
EP2 WT antisense (5
0 to 30) CGA TAA GTG GCG CCT GTA GAA GT
EP2
/ sense (50 to 30) GGT GGG GGt GGG GTG GGA TTA GAT
EP2
/ antisense (50 to 30) GAG CAG CGG CAG GGA ACA GAA
GAG
Weanling pups in each litter were identified as WT, EP2
þ /,
and EP2
/. Littermate groupings were used for each experiment.
UV irradiation and tumor measurements
Six- to seven-week-old mice weighing between 25 and 30 g were
used for experiments. The mice were housed five per cage with
12 hours light/dark cycles. They were allowed access to water and
food ad libitum. All experimental procedures received approval by
the Institutional Laboratory Animal Care and Use Committee of the
University of Rochester Medical Center.
WT, EP2
þ /, and EP2
/ mice was exposed to UV irradiation in
groups of two or three using a bank of four UVA Sun 340 sunlamps
(Q-Panel Lab Products, Cleveland, OH), as described previously
(Pentland et al., 2004), which emit light between 295 and 390 nm
(combined UVA & UVB output; termed UVR). Lamp output was
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measured by an IL1700 light meter (International Light, New-
buryport, MA) using an SED 240 probe for measurement of the UVB
portion of the lamp spectrum. The SED 240 probe detects
wavelengths from 255 to 320 nm. Doses stated represent this portion
of the lamp output only. Mice were exposed to the UVR lamps at a
distance of 15 inches. Heat produced by the lamp was negligible
under these conditions. The total dose was calculated using the flux
measured and the length of exposure. Lamp output was monitored
weekly. For chronic photocarcinogenesis experiments, animals were
irradiated initially with 120 mJ/cm2 of UVR, three times per week,
increasing the exposure dose 10% each week for 15 weeks. Animals
were then observed for an additional 15 weeks. In chronically
irradiated animals, the maximum length of exposure was 300 min-
utes and the cumulative UVB dose 12 J/cm2. The UVA cumulative
dose was 658 J/cm2. Ten animals completed the irradiation protocol
in the WT and EP2
/ groups. Nine animals were in the EP2
þ / group.
Animal weight, tumor numbers, and tumor size were measured
weekly throughout the protocol.
Histology
At the killing, the left half of the dorsal skin from each mouse was
snap-frozen in liquid nitrogen and stored at 801C. The remaining
dorsal skin was divided into seven pieces, fixed in 10% neutral
buffered formalin, routinely processed, and embedded in seven
paraffin blocks. Paraffin sections (5 mm) stained with hematoxylin
and eosin were used for histologic analysis of UV-induced
alterations in morphology. Tissue sections used for measuring UV
effects on epidermal thickness were oriented with great care to
assure that a true vertical section was obtained. Characterization of
mouse tumor morphology was performed by dermatopathologist Dr.
Scott using blinded slide sets. All tumors45 mm in diameter evident
in sections cut from paraffin-embedded samples were examined.
Blocks were not cut to exhaustion to permit access to every large
tumor. All tumors that were at the accessable edge of each block
were included in the histologic studies.
Keratinocyte proliferation
Keratinocyte proliferation in mouse epidermis was measured using
immunohistochemical detection of BrdU. Mice were injected
intraperitoneally with 0.3 ml of a 20 mM solution of BrdU (Boehrin-
ger Mannheim, Mannheim, Germany), 3 hours before the killing.
BrdU was detected with a BrdU staining kit (Zymed Labs Inc., San
Francisco, CA) according to the manufacturer’s recommendations,
and staining was visualized with the VIP chromagen (Vector,
Burlingame, CA.). The sections were briefly counterstained with
blue/methyl green (Rowley Biochemical Inst., Danvers, MA). A
section of small intestine was included from each mouse as a
positive control for BrdU incorporation. Quantitation of BrdU
proliferation was blinded, and expressed as the ratio of BrdU-
positive nuclei per 10,000 mm2. A minimum of 6–8 fields was
evaluated per section. BrdU-labeled cells in normal or tumor tissue
were tabulated separately. Cells within dermal follicular cysts were
not included in the counts (Pentland et al., 2004).
Measurement of metalloproteinases in mouse epidermis
Analysis of metalloproteinases was accomplished using snap-frozen
curetted epidermal tissue lysates prepared by homogenization in
M-PER buffer (Pierce cat no.78501, Rockford, IL). Once homogenized,
extracts were centrifuged at 14,000 g, then supernatants were
collected and stored at 801C until use. Total protein content was
determined by the BCA method (Pierce, Rockford, IL). MMP-2 and
MMP-9 enzymatic activity was analyzed by using the fluorescent
substrate Dnp-PChaGCHAK9Nma as per the manufacturer’s instruc-
tions (BIOMOL, Plymouth Meeting, PA). Samples from WT and
EP2
/ animals were assayed at 371C using a substrate concentration
of 10mM in buffer containing 500 mM HEPES, 100 mM CaCl2, and
0.5% Brij-35 (pH 7.0) for MMP-9 or 100 mM ZnCl2 and 500 mM
MOPS for MMP-2. Fluorometric measurements were made in a
Molecular Device spectrofluorometer. Fluorescence was detected
using excitation at 340 nm, and emission measured at 440 nm.
As a second method to determine the amount of metalloprotein-
ases in epidermal tissue, zymography was performed. Zymographic
analysis to detect gelatinolytic activity was performed in epidermal
extracts prepared by homogenization in lysis buffer (15 mM HEPES
(pH 7.4), 250 mM sucrose, 10 mM EDTA, and 0.1% NP40) containing
a 1:100 volume of protease inhibitors (Protease inhibitor cocktail
(Sigma, St Louis, MO)). Protein extracts solubilized in 4 non-
reducing sample buffer were loaded on to an 8% polyacrylamide gel
containing 0.1% gelatin, and proteins separated by electrophoresis.
Gels were washed in two changes of 2.5% Triton X-100 solution at
room temperature to remove SDS from the gel, then washed three
times in milli-Q water. Gels were then incubated in activation buffer
containing 50 mM Tris (pH 7.5), 10 mm CaCl2, and 0.1 mM ZnCl for
at least 18 hours at 371C. Gels were stained with Coomassie solution
(0.25% Coomassie Brillant Blue (BioRad, Hercules, CA), 10% glacial
acetic acid, and 40% methanol) for 15 minutes, then destained until
lytic areas were optimally visualized.
Measurement of prostaglandins in mouse epidermis
After the killing, mouse dorsal skin was snap-frozen and the
epidermis curetted directly into ice-cold methanol. Efficacy of
curettage as a method for removing only the epidermis was
documented by histology of remaining dermis, which was intact.
In addition, multiple random extracts were tested for their
thromboxane content as an indication of the presence of platelet
metabolites, and no contamination of samples was found. Thrombo-
xane B2 (Cayman Chemical, Ann Arbor, MI) was therefore used to
spike samples as a method of estimating extraction efficiency.
Samples were buffered with 0.1 M NaH2PO4 (pH 4.0) and then
individually loaded onto C-18 solid-phase extraction cartridges
(Waters, Milford, MA) preconditioned with ethanol and H2O (pH
4.0). After washing with H2O (pH 4.0) and hexane, samples were
eluted by gravity with ethyl acetate/1% methanol. The eluant was
dried under nitrogen and reconstituted with EIA Buffer (Cayman
Chemical, Ann Arbor, MI). The PGE2 content in the samples were
determined using PGE2 EIA kits as per the manufacturer’s instruc-
tions (Cayman Chemical, Ann Arbor, MI). Similarly, quantities of
thromboxane B2 were determined with a Thromboxane B2 EIA kit
(Cayman Chemical, Ann Arbor, MI) and extraction efficiencies
calculated from the results.
Statistical analyses
For experiments evaluating the number of tumors in irradiated
animals, a Mann–Whitney test was performed on each group (van
Belle et al., 2004). To assess differences in tumor sizes, Fisher’s exact
test was used (van Belle et al., 2004). Other statistical analyses were
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performed by computer assisted two-tailed analysis of variance
(ANOVA) to compare between group means. To assess BrdU and
changes in epidermal thickness, Student’s t-test was used (van Belle
et al., 2004). A P-value of 0.05 (Pp0.05) was considered statistically
significant. Data are expressed as mean 7SEM.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported by a grants from the National Institutes of Health CA
117821-06A1 (Pentland) and GM15431 (Breyer). The authors acknowledge
Dr Sandra Schnieder for her wise support, Kieran H. McGrath and Carol
Tanck for their technical assistance, and Carol Pearce for her patient
administrative assistance.
REFERENCES
Baratelli FE, Heuze-Vourc’h N, Krysan K, Dohadwala M, Riedl K, Sharma S
et al. (2004) Prostaglandin E2-dependent enhancement of tissue
inhibitors of metalloproteinases-1 production limits dendritic cell
migration through extracellular matrix. J Immunol 1739:5458–66
Black HS, deGruijl FR, Forbes PD, Cleaver JE, Ananthaswamy HN, de Fabo
EC et al. (1997) Photocarcinogenesis: an overview. J Photochem
Photobiol B 401:29–47
Bresalier RS (2002) Chemoprevention of intestinal polyposis by COX-2
inhibition: from mouse to man. Gastroenterology 1221:234–6
DuBois RN (2001) New paradigms for cancer prevention. Carcinogenesis
225:691–2
Egan KM, Wang M, Fries S, Lucitt MB, Zukas AM, Pure E et al. (2005)
Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabiliza-
tion by cyclooxygenase-2 inhibition combined with thromboxane
receptor antagonism. Circulation 1113:334–42
Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA et al. (1999)
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2
inhibitor, and indomethacin against ultraviolet light-induced skin
carcinogenesis. Mol Carcinog 254:231–40
Fitzgerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med
35117:1709–11
Furberg CD, Psaty BM, FitzGerald GA (2005) Parecoxib, valdecoxib, and
cardiovascular risk. Circulation 1113:249
Geller AC, Annas GD (2003) Epidemiology of melanoma and nonmelanoma
skin cancer. Semin Oncol Nurs 191:2–11
Hata AN, Breyer RM (2004) Pharmacology and signaling of prostaglandin
receptors: multiple roles in inflammation and immune modulation.
Pharmacol Ther 1032:147–66
Kawamori T, Kitamura T, Watanabe K, Uchiya N, Maruyama T, Narumiya S
et al. (2005) Prostaglandin E receptor subtype EP(1) deficiency inhibits
colon cancer development. Carcinogenesis 262:353–7
Kawamori T, Wakabayashi K (2002) COX-2 and prostanoid receptors: good
targets for chemoprevention. J Environ Pathol Toxicol Oncol 212:149–53
Kennedy CR, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD et al. (1999)
Salt-sensitive hypertension and reduced fertility in mice lacking the
prostaglandin EP2 receptor. Nat Med 52:217–20
Konger RL, Billings S, Thompson A, Morimiya A, Ladenson JH,
Landt Y et al. (2005) Immunolocalization of low affinity prostaglandin
E2 receptors, EP1 and EP2, in adult human epidermis. J Invest Dermatol
1245:965–70
Konger RL, Malaviya R, Pentland AP (1998) Growth regulation of primary
human keratinocytes by prostaglandin E receptor EP2 and EP3 subtypes.
Biochim Biophys Acta 14012:221–34
Konger RL, Scott GA, Landt Y, Ladenson JH, Pentland AP (2002) Loss of the
EP2 prostaglandin E2 receptor in immortalized human keratinocytes
results in increased invasiveness and decreased paxillin expression. Am J
Pathol 1616:2065–78
Lenzer J (2004) US government agency to investigate FDA over rofecoxib.
BMJ 329:935
Marks F, Furstenberger G (2000) Cancer chemoprevention through interrup-
tion of multistage carcinogenesis. The lessons learnt by comparing
mouse skin carcinogenesis and human large bowel cancer. Eur J Cancer
363:314–29
Martinez JC, Otley CC, Stasko T, Euvrard S, Brown C, Schanbacher CF et al.
(2003) Defining the clinical course of metastatic skin cancer in organ
transplant recipients: a multicenter collaborative study. Arch Dermatol
1393:301–6
Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T et al.
(2002) Involvement of prostaglandin E receptor subtype EP(4) in colon
carcinogenesis. Cancer Res 621:28–32
Nova D, Le Griel C, Holvoet S, Gentilhomme E, Vincent C, Staquet MJ et al.
(2003) Comparative studies on the secretion and activation of MMPs in
two reconstructed human skin models using HaCaT- and HaCaT-ras-
transfected cell lines. Clin Exp Metastasis 208:675–83
Ortiz-Urda S, Garcia J, Green CL, Chen L, Lin Q, Veitch DP et al. (2005) Type
VII collagen is required for Ras-driven human epidermal tumorigenesis.
Science 307:1773–6
Overall CM (2002) Molecular determinants of metalloproteinase substrate
specificity. Mol Biotechnol 22:51–85
Panteleyev AA, Botchkareva NV, Sundberg JP, Christiano AM, Paus R (1999)
The role of the hairless (hr) gene in the regulation of hair follicle catagen
transformation. Am J Pathol 1551:159–71
Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R (1999) Reduction of
UV-induced skin tumors in hairless mice by selective COX-2 inhibition.
Carcinogenesis 2010:1939–44
Pentland AP, Scott G, VanBuskirk J, Tanck C, LaRossa G, Brouxhon S
(2004) Cyclooxygenase-1 deletion enhances apoptosis but does not
protect against ultraviolet light-induced tumors. Cancer Res 6416:
5587–91
Petter G, Haustein UF (2000) Histologic subtyping and malignancy
assessment of cutaneous squamous cell carcinoma. Dermatol Surg
26:521–30
Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS (2002)
Chemopreventive properties of a selective inducible nitric oxide
synthase inhibitor in colon carcinogenesis, administered alone or in
combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Cancer Res 621:165–70
Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V et al. (1995)
Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal
anti-inflammatory agent. Cancer Res 557:1464–72
Saarialho-Kere UK, Pentland AP, Birkedal-Hansen H, Parks WC,
Welgus HG (1994) Distinct populations of basal keratinocytes express
stromelysin-1 and stromelysin-2 in chronic wounds. J Clin Invest
941:79–88
Saladi RN, Persaud AN (2005) The causes of skin cancer: a comprehensive
review. Drugs Today (Barcelona) 411:37–53
Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD et al. (2001)
Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-
regulated in carcinomas of the cervix: a possible autocrine/paracrine
regulation of neoplastic cell function via EP2/EP4 receptors. J Clin
Endocrinol Metab 865:2243–9
Sawicki G, Marcoux Y, Sarkhosh K, Tredget EE, Ghahary A (2005) Interaction
of keratinocytes and fibroblasts modulates the expression of matrix
metalloproteinases-2 and -9 and their inhibitors. Mol Cell Biochem
2691–2692:209–16
Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T
et al. (2004) Downregulation of prostaglandin E receptor subtype EP3
during colon cancer development. Gut 538:1151–8
Shoji Y, Takahashi M, Takasuka N, Niho N, Kitamura T, Sato H et al.
(2005) Prostaglandin E receptor EP3 deficiency modifies tumor
outcome in mouse two-stage skin carcinogenesis. Carcinogenesis
26:2116–22
Singh-Ranger G, Mokbel K (2002) The role of cyclooxygenase-2 (COX-2) in breast
cancer, and implications of COX-2 inhibition. Eur J Surg Oncol 287:729–37
www.jidonline.org 445
S Brouxhon et al.
EP2 Receptor Effects on Photocarcinogenesis
Sonoshita M, Takaku K, Oshima M, Sugihara K, Taketo MM (2002)
Cyclooxygenase-2 expression in fibroblasts and endothelial cells of
intestinal polyps. Cancer Res 6223:6846–9
Steffensen B, Hakkinen L, Larjava H (2001) Proteolytic events of wound-
healing – coordinated interactions among matrix metalloproteinases
(MMPs), integrins, and extracellular matrix molecules. Crit Rev Oral Biol
Med 125:373–98
Sung YM, He G, Fischer SM (2005) Lack of expression of the EP2 but not EP3
receptor for prostaglandin E2 results in suppression of skin tumor
development. Cancer Res 6520:9304–11
Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A et al. (2002)
Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal
differentiation and reduces mouse skin tumorigenesis. Cancer Res
6212:3395–401
Umar A, Viner JL, Hawk ET (2001) The future of colon cancer prevention. Ann
NY Acad Sci 952:88–108
van Belle G, Fisher LD, Heagerty PJ, Lumley TS (2004) Biostatistics: a methodology
for the health sciences. Edition n, translator. New York: Wiley & Sons
Williams C, Shattuck-Brandt RL, DuBois RN (1999) The role of COX-2 in
intestinal cancer. Ann NY Acad Sci 889:72–83
446 Journal of Investigative Dermatology (2007), Volume 127
S Brouxhon et al.
EP2 Receptor Effects on Photocarcinogenesis
